Biohaven (BHVN) has withdrawn its application for a marketing authorization of Dazluma to treat spinocerebellar ataxia genotype 3, an inherited brain disorder, the European Medicines Agency said Friday.
Biohaven shares were down more than 11% in recent trading.
The EMA said the application was withdrawn after the regulator evaluated the information from the firm and prepared questions.
"Based on the review of the data and the company's response to the Agency's questions, at the time of the withdrawal, the Agency had some concerns, and its provisional opinion was that Dazluma could not have been authorized for the treatment of spinocerebellar ataxia," the regulator said.
The EMA also said it considered that no conclusions could be drawn as the findings of the main study did not show that Dazluma was more effective than placebo for the treatment of spinocerebellar ataxia.
Price: 20.70, Change: -2.70, Percent Change: -11.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。